Table 2

 Characteristics of men and women in study

CharacteristicsMen(n = 71)Women(n = 51)
Data are presented as median values (interquartile range) unless stated otherwise.
BHR, bronchial hyperresponsiveness; pre BD, before administration of bronchodilator; post BD, after administration of bronchodilator.
*Calculated for individuals who ever used inhaled corticosteroids only.
Differences tested by χ2 test (categorical variables) or Mann-Whitney U test (continuous variables). Significant difference between males and females: †p<0.0001; ‡p = 0.035; §p = 0.018; ¶p = 0.040.
Age of onset of symptoms (years)6 (2–22)6 (3–21)
Untreated period (years)14 (4–22)16 (9–25)
Age at start of inhaled corticosteroids (years)40 (34–48)45 (35–53)
Mean daily dose of inhaled corticosteroids (μg/day)*794 (527–1129)618 (400–1114)
Period of inhaled corticosteroid use (years)13.6 (7.0–19.4)14.0 (8.5–20.7)
Duration of inhaled corticosteroid use (years of 100 μg use daily)*110.1 (47.7–165.9)88.6 (46.4–155.9)
Initial testing
    Age (years)27 (21–34)30 (24–37)
    FEV1 % predicted pre BD (%)56 (45–71)56 (39–69)
    FEV1 % predicted post BD (%)85 (66–97)87 (68–97)
    BHR ⩽16.0 mg/ml (%)8688
    ⩾1 positive skin test (%)8688
    Blood eosinophils (×106/l)341 (237–534)280 (215–481)
    Reversibility (% predicted)24 (18–32)28 (17–33)
    Smoking
        Pack years smoking2.4 (0–7.2)†0 (0–0.5)
        Non/ex/current smokers (%)34/10/56†71/0/29
Re-examination
    Age (years)53 (46–59)57 (50–62)
    FEV1 % predicted pre BD (%)57 (42–74)61 (39–81)
    FEV1 % predicted post BD (%)70 (54–85)‡78 (62–95)
    BHR ⩽16.0 mg/ml (%)8885
    ⩾1 positive skin test (%)7773
    Blood eosinophils (×106/l)130 (70–220)132 (66–220)
    Reversibility (% predicted)12 (8–16)§15 (9–21)
    Total IgE (IU/l)96 (27–442)¶47 (25–193)
    Total IgE ⩾120 IU/l (%)4632
    Smoking
        Pack years smoking8.4 (0.3–16.9)†0 (0–3.6)
        Non/ex/current smokers (%)24/47/30†71/20/10